Orally Disintegrating Tablet Market

According to Stratistics MRC, the Global Orally Disintegrating Tablet Market is accounted for $15,079.74 million in 2023 and is expected to reach $38,269.71 million by 2030 growing at a CAGR of 14.23% during the forecast period. Orally disintegrating tablets, sometimes referred to as melt-in-mouth, fast-dissolving, or fast-disintegrating tablets, are solid dosage forms that, when placed in the oral cavity or on the tongue, dissolve or disintegrate quickly. Moreover, the rapid disintegration and dissolution of these tablets, which enable quick drug absorption through the oral mucosa, are ensured by their formulation, which utilizes a variety of technologies. In order to give patients a satisfying experience while preserving the effectiveness of the active pharmaceutical ingredient, the formulation of ODTs requires a careful balancing act between taste, stability, and manufacturability.

According to the FDA (2008), orodispersible tablets should disintegrate within 30 s using the USP disintegration test [23]. Formulations F1 and F2 showed a disintegration time of less than 30s.

Market Dynamics: 

Driver: 

Higher bioavailability rate

The bioavailability of some medications may be improved by ODTs. Higher drug concentrations in the bloodstream are the consequence of their dissolution in the oral mucosa, which evades the liver's first-pass metabolism. Additionally, ODTs are now included in a variety of pharmaceutical portfolios because of their particular value for medications with low bioavailability and those that undergo extensive hepatic metabolism.

Restraint:

Insufficient drug compatibility

Every medication cannot be formulated for ODT. Certain medications may not taste well, may not stabilize well in damp environments or dissolve quickly, or may not have the physical qualities needed to be used as oral drug delivery technologies. Furthermore, this restriction might make it more difficult to offer more ODT for particular drug compounds and therapeutic classes.

Opportunity:

Increased access to pediatric drugs

In pediatric medicine, ODTs offer a great deal of potential. The market for kid-friendly dosage forms has expanded in tandem with the growth in the need for pediatric healthcare. ODTs address the difficulties related to pediatric medication adherence by providing a tasty and simple-to-administer alternative. Moreover, pharmaceutical companies can broaden their product offerings by creating ODT formulations for a variety of pediatric drugs, such as allergy treatments and antibiotics.

Threat:

Patent expiration and intellectual property

Patents and intellectual property rights frequently shield ODT formulations, which can restrict access to exclusive technology and taste-masking strategies. Especially for well-known ODT products, generic manufacturers may enter the market as patents expire, which could lead to price erosion and increased competition. Additionally, the income of ODT drug manufacturers may be threatened by this.

Covid-19 Impact: 

The Orally Disintegrating Tablet (ODT) market has been impacted by the COVID-19 pandemic in a number of ways. Although contactless, self-administered dosage forms (ODTs) have been shown to be beneficial, the development and accessibility of ODT products have been hampered by supply chain disruptions, delays in clinical trials, and regulatory processes. Additionally, the pandemic hastened the adoption of telemedicine, opening doors for home delivery of ODT medications and remote prescribing. Challenges have included shifting healthcare priorities, reallocating resources toward pandemic response efforts, and facing financial ramifications. These have especially affected funding and investment for new ODT research and development.

The Proton Pump Inhibitors segment is expected to be the largest during the forecast period

In the Orally Disintegrating Tablet Market, the segment with the largest market share is proton pump inhibitors. Medications known as proton pump inhibitors (PPIs) are frequently prescribed to treat gastrointestinal disorders, peptic ulcers, and gastroesophageal reflux disease (GERD). They relieve patients experiencing symptoms related to acid reflux by decreasing the production of stomach acid. The prominence of this segment is partly due to the long-term use of PPIs for chronic conditions and the widespread prevalence of disorders related to acidity. Moreover, PPIs are now a significant player in the pharmaceutical industry due to their expanded market reach and availability in both prescription and over-the-counter (OTC) versions.

The Respiratory Disorders segment is expected to have the highest CAGR during the forecast period

The respiratory disorders segment is expected to grow at the highest CAGR. A broad spectrum of illnesses is categorized as respiratory disorders, such as multiple respiratory infections, asthma, and chronic obstructive pulmonary disease (COPD). The need for novel treatments is fueled by the rising incidence of respiratory illnesses worldwide, which is a result of factors like smoking, air pollution, and aging populations. Improvements in precision medicine, biologics, and inhalation technologies are revolutionizing the treatment of respiratory illnesses. Furthermore, the COVID-19 pandemic has raised awareness of respiratory health issues and prompted more research and development activities.
 
Region with largest share:

In the oral disintegrating tablet market, North America has the largest share. Its strong healthcare system, large healthcare budget, extensive R&D, and sizable patient base with a variety of medical conditions are all considered contributing factors to its dominance in the field. Due to its sophisticated medical technology, strong research institutions, and emphasis on healthcare innovation, the United States in particular is a major force behind pharmaceutical advancements. Moreover, by leading the world's pharmaceutical industry, North America maintains its position thanks to its proactive response to new healthcare challenges.

Region with highest CAGR:

The oral disintegrating tablet market is growing at the highest CAGR in the Asia-Pacific region. A number of factors, including growing economic development, increased healthcare awareness, and increased access to healthcare services, are responsible for this amazing growth. With major investments from healthcare companies, Asia-Pacific has emerged as a key hub for pharmaceutical development, clinical trials, and medical research. Furthermore, the region is experiencing swift progress in biotechnology, novel pharmaceuticals, and healthcare infrastructure, establishing it as a primary catalyst for expansion and novelty in the worldwide pharmaceutical industry.

Key players in the market

Some of the key players in Orally Disintegrating Tablet market include Takeda Pharmaceutical Company Limited, AstraZeneca, Mylan N.V, Otsuka Pharmaceutical Co., Ltd., Merck & Co., Inc., Pfizer Inc, Johnson & Johnson Services, Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Eli Lily and Company, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd. and Dr. Reddy's Laboratories Ltd., Bausch Health and Bayer AG.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis to accelerate the development of next-generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design novel cell and gene therapy products, strengthening AstraZeneca’s growing offering in this space.

In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.
 
In January 2023, Takeda announced that it has entered into an exclusive licensing agreement with HUTCHMED (China) Limited and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau.

Products Covered:
• Orodispersible Tablets
• Fast Dissolving Tablets
• Sublingual Tablets
• Other Products 
 
Drug Classes Covered:
• Anti-Psychotics
• Anti-Epileptics
• Central Nervous System (CNS) Stimulants
• Anxiolytics
• Anti-Parkinsonian Drugs
• Anti-Hypertensives
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Anti-Allergy Drugs
• Proton Pump Inhibitors
• Other Drug Classes 

Indications Covered:
• Central Nervous System (CNS) Diseases
• Gastrointestinal Diseases
• Respiratory Disorders
• Cyclical Vomiting Syndrome (CVS) Disorders
• Allergy
• Other Indications

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies 

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances